natgillin/translations-raw huggingface dataset:
further excipients ad 100 wt.-% Particularly preferred is an extended release tablet formulation consisting of Pramipexole-dihydrochloride monohydrate, Hypromellose 2208, Corn starch, Carbomer 941, Colloidal silicon dioxide and Magnesium stearate, 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da se sastoji od pramipeksol-dihidroklorid monohidrata, hipromeloze 2208, kukuruznog škroba, karbomera 941, koloidnog silicij dioksida i magnezijevog stearata.
in which process 1,4-difluorobenzene is reacted in the presence of a base with a compound of formula (III-a) 
IL. HR P20090675 TI u prisutnosti baze, kako bi se dobilo spoj formule (IV) u,
Cup (1) according to claim 1, characterized in that the cup (1) is a package for beverages. 
Spremnik (1) prema patentnom zahtjevu 1, naznačen time da je spremnik (1) ambalaža za pića.
Method according to any one of claims 1 to 11, characterised in that at least one amino acid of at least one structural loop region is modified by site-directed random mutation. 
Postupak u skladu s bilo kojim zahtjevom 1 do 24, naznačen time, da je nukleotidna sekvenca barem jednog područja petlje modificirana na jednu stranu usmjerenom i/ili nasumičnom i/ili polu-nasumičnom mutacijom.
a wellhead arranged in correspondence with or close to an end of the first anchoring pipe; 
glavu bušotine (3), koja se nalazi uz ili blizu kraja prve sidrene cijevi (30);
The process of claim 7, wherein the hydrocarbon fraction boiling in a range of jet fuel is used directly as a jet fuel without blending; or 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da se frakcija mlaznog goriva (40) koristi izravno kao mlazno gorivo bez miješanja; ili se dizelska frakcija koristi izravno kao dizelsko gorivo bez miješanja.
reacting the compound of the Formula (II) with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60° C., to obtain the compound of the Formula (I); and optionally purifying the obtained crude compound of the Formula (I). 
HR P20100102 TI iv) reakciju dobivenog 17a-cijanometil-17B-hidroksi-estr-5(10)-en-3-ona formule (II) sa 1-1.5 ekvivalenta piridinij tribromida u otopini piridina pri temperaturi između 0 i 60%C, zatim pročišćavanje dobivenog sirovog dienogesta formule (IT) rekristalizacijom i preparativnom HPLC.
prior to step (ii): pressing said beam-like block of wood; 
(vi) prije faze (ii): prešanje navedenog bloka od drva koji ima oblik grede;
is selected from the group consisting of C1-6 alkyl and C3-8 cycloalkyl; 
je odabran iz skupine koju čine C1-6 alkil i C3-8cikloalkil;
Use of (a) a B2 agonist for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in 1 or 2 for the treatment of a respiratory disease which responds to M3 antagonism in a patient. 
Antagonist M3 muskarinskih receptora, za uporabu u skladu sa zahtjevom 16, naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 1li 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
The process according to claim 1, wherein, during step c), the temperature at which the bromination reaction is performed is from 20° C. to 40° C. below the boiling point of the volatile fatty acid. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da je tijekom koraka c) temperatura pri kojoj se provodi reakcija bromiranja od 20*C do 40*€ manja od temperature vrenja hlapive masne kiseline.
The method of claim 1, wherein the pellets of step a) comprise a maximum of the particle size distribution d50 of ≥200 um to ≤1500 um. 
Postupak prema jednom od patentnih zahtjeva 1 do 7, naznačen time što peleti dobiveni u koraku a) imaju maksimalnu raspodjelu veličine čestica d50 od ≥ 200 µm do ≤ 1500 µm.
a LDPC encoder configured to LDPC-encode the BCH-encoded Layer 1 signaling data to generate at least one LDPC parity bit; and a puncturing means configured to perform puncturing on the generated LDPC parity bit. 
LDPC koder konfiguriran za LDPC-kodiranje BCH-kodiranih signalnih podataka L1l zbog stvaranja LDPC paritetnih bitova; i sredstvo probijanja konfigurirano za probijanje na stvorenim LDPC paritetnim bitovima.
The mixture is kept under stirring for 30 min, then added with diisopropylaminomethyl-polystyrene (1.5 eq) and intermediate (1') (1 eq). 
Smjesa je miješana 30 min, te je dodan diizopropilaminometilpolistiren (1.5 ekviv.) i međuprodukt (1') (1 ekviv.).
Presented at the 96th meeting of the Society for Endocrinology, 7-9th November 2005). 
Prikazan na 96-om savjetovanju Udruge za Endokrinologiju, 7-9. 11. 2005).
A compound of Formula (IV): or a pharmaceutically acceptable salt thereof, wherein: 
Farmaceutski pripravak koji sadrži spoj formule: [image] ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač, katalizator ili prenositelj.
and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-1 or ring R-2 
R* i R' su uzeti zajedno sa kontinuiranim vezujućim atomima dušika i ugljika tako da formiraju izborno supstituiran prsten R-1 nN £
an encoder configured to encode the preamble data; a time-interleaver configured to time-interleave the encoded preamble data by row-column twisted fashion, in which input cells are serially written into interleaving memory in a diagonal direction, and serially read out row-wise, wherein the time-interleaving is performed without considering pilot position; 
sredstvo (306) za stvaranje podatkovnih rezova uključujući kodirane PLP podatke; sredstvo (308) za umetanje vremena u stanice podataka na način prelamanja redova-stupaca gdje su stanice za unos podataka serijski zapisane u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova;
Use of a tumour associated peptide according to any one of Claims 1 to 3 or a nucleic acid according to Claim 4 or 5 or an expression vector according to Claim 6 for the manufacture of a medicament for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumours which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence as given in any of Claims 1 or 2. 
Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahljeva 1 ili 2.
In another aspect, the invention provides compound of Formula III: 
Tvar formule III ili njena farmaceutski prihvatljiva sol, pri čemu
A method of producing a piceatannol-containing composition according to claim 2, wherein the method comprises: pulverizing a passion fruit seed; adding any one of an aqueous alcohol-based solvent and an aqueous ketone-based solvent; stirring the mixture to extract piceatannol into the solvent, thereby obtaining a first extract; adding the other not selected in the above out of the aqueous alcohol-based solvent and the aqueous ketone-based solvent to a residue not collected as the extract; stirring the mixture to extract piceatannol into the solvent, thereby obtaining a second extract; and mixing the first extract and the second extract. 
Postupak proizvodnje sastava koji sadrži piceatanol, prema zahtjevu 7 ili 8, naznačen time, da postupak obuhvaća: dodavanje bilo koje od vodenih otopina, vodene otopine na osnovi alkohola i vodene otopine na osnovi ketona u sjeme Passiflora edulis sims; miješanje smjese u svrhu ekstrakcije piceatanola u otopini, čime se dobiva prvi ekstrakt; dodavanje neke druge vodene otopine neodabrane od gore navedenih, naime osim vodene otopine na bazi alkohola i vodene otopine na bazi ketona, u talog koji nije sakupljen kao ekstrakt; miješanje smjese u svrhu ekstrakcije piceatanola u otopini, čime se dobiva drugi ekstrakt; i miješanje prvog ekstrakta s drugim ekstraktom.
contacting the antigen with a collection of antibodies or functional fragments thereof according to claim 1, and (b) selecting one or more antibodies or antibody fragments that bind to said antigen. 
(a) stavljanju u kontakt antigena sa zbirkom protutijela, ili njihovih funkcionalnih fragmenata, u skladu s patentnim zahtjevom 1, i
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
P4-P3-P2-P1 (Formula II), wherein P4 is an amino acid residue at the amino end, P1 is an amino acid residue at the carboxyl end, P1 is an arginine residue or a lysine residue, and the amino acid sequence of Formula II is cleavable at the carboxyl end of P1 by furin. 
prikazan formulom P4-P3-P2-P1, gdje je P4 neki akinokiselinski ostatak na amino kraju, P1 je aminokiselinski ostatak na karboksilnom kraju, P1 je ostatak arginina ili lizina a spomenuta sekvencija se može cijepati furinom na karboksilnom kraju P1;
The compound and/or the at least one pharmaceutically acceptable salt thereof for use according to claim 3, wherein the cancer is chosen from lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer. 
Spoj ifili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 3, naznačeno time da je karcinom odabran od sljedećih: karcinom pluća, karcinom glave i vrata, karcinom kolorektuma, karcinom ždrijela, epidermoidni karcinom i karcinom pankreasa.
The fusion peptide according to claim 9, wherein component (III) comprises at least four amino acid residues, or comprises preferably at least 10 amino acid residues, or comprises more preferably at least 20 amino acid residues. 
Fuzijski peptid prema patentnom zahtjevu 9, naznačen time da komponenta (Ill) obuhvaća najmanje četiri aminokiselinska ostatka, ili poželjno obuhvaća najmanje 10 aminokiselinskih ostataka, ili još poželjnije obuhvaća najmanje 20 aminokiselinskih ostataka,
. A compound according to claim 16 or a composition according to any one of claims 17 to 21 and 24 for use in a method of treatment of a disorder of the central nervous system; damage to the central nervous system; a cardiovascular disorder; a gastrointestinal disorder; diabetes insipidus, or sleep apnea. 
Spoj u skladu s bilo kojim zahtjevom 1 do 11, naznačen time, da se koristi u postupku liječenja poremećaja središnjeg živčanog sustava; oštećenja središnjeg živčanog sustava; kardiovaskularnog poremećaja; gastrointestinalnog poremećaja; dijabetesa insipidusa ili apneje spavanja.
Process for the manufacture of a nutritional composition according to claim 1 to 13 comprising preparing an aqueous phase comprising protein and digestible carbohydrates and preparing a fat phase comprising lipids, wherein phospholipids are present in the aqueous and/or fat phase, wherein the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, wherein the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 30 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, mixing the fat and aqueous phase and homogenizing the mixture of fat and aqueous phase into an oil-in-water emulsion with lipid globules at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
20. Postupak proizvodnje nutritivnog pripravka prema zahtjevima 1 do 13 koji obuhvaća pripremu vodene faze koja sadrži proteine i probavljive ugljikohidrate te pripremu masne faze koja sadrži lipide, gdje su fosfolipidi prisutni u vodenoj i/ili masnoj fazi, gdje sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, gdje sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida, zatim miješanje masne i vodene faze te homogeniziranje smjese masne i vodene faze u emulziju tipa ulje-u-vodi s lipidnim globulama koje su barem djelomično obložene fosfolipidima na
A pharmaceutical composition comprising the antibody or antibody fragment thereof of any one of claims 1 to 6 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži bispecifično antitijelo ili njegov bispecifični fragment antitijela prema bilo kojem zahtjevu 1 ili 21 farmaceutski prihvatljiv nosač.
Threading device according to claim 3, characterized in that the beam (18; 118) comprises a plurality of teeth (28; 128). 
Naprava za uvođenje užeta oko alke prema zahtjevu 3, naznačena time da letva (18; 118) sadrži veći broj zubaca
Also provided is a pharmaceutical composition comprising (a) a B2-agonists; and (b) an M3 antagonist of the invention, in association with (c) a pharmaceutically acceptable carrier or diluent. 
Također je omogućen farmaceutski pripravak koji sadrži (a) kortikosteroid 1 (b) M3 antagonist sukladno predmetnom izumu u kombinaciji s (c) farmaceutski prihvatljivim nosačem ili razrjeđivačem.
Said apparatus comprising: a fermentation vessel 10 for fermenting wort with a biologically active yeast to produce a fermented liquid containing yeast, alcohol, polyphenols and protein, the fermentation vessel 10 being arranged to receive wort and comprises an outlet 13 for outputting a fermented liquid containing yeast, alcohol, polyphenols and protein; 
* > posudu (10) za fermentaciju namijenjenu fermentaciji sladovine pomoću biološki aktivnog kvasca kako bi se proizvela fermentirana tekućina koja sadrži kvasac, alkohol, polifenole i proteine, gdje je posuda (10) za fermentaciju prilagođena da primi mlado pivo 1 sadrži odvod (13) namijenjen za pražnjenje fermentirane tekućine koja sadrži kvasac, alkohol, polifenole i proteine;
Method according to one of the claims 23 to 30 or use according to one of the claims 31 to 33 wherein the patient has insufficient glycemic control despite diet and exercise or despite monotherapy with an antidiabetic agent, in particular with metformin. 
Farmaceutski sastav za uporabu prema zahtjevu 9, naznačen time, da pacijent ima nedovoljnu glikemijsku kontrolu usprkos posebnoj prehrani i tjelovježbi ili usprkos monoterapiji s antidijabetičkim sredstvom, posebno s metforminom.
R292P and V305I; at least one substitution of three amino acid residues, the substitutions being selected from the group consisting of: 
(C) najmanje jedne zamjene tri aminokiselinska ostatka, gdje se navedene zamjene bira iz skupine koju čine:
A container assembly (100) comprising: a container (102); and the cap (104) of any one of claims 1-9 coupled to the container (102). 
Sklop spremnika (100) naznačen time da sadrži: spremnik (102); 1 poklopac (104) prema barem jednom od prethodnih zahtjeva spojen na spremnik (102).
The method of item 7, wherein the molar ratio of formic acid versus 3-(2-methyl-5-nitro-4-oxoquinazolin-3(4 H)-yl)piperidine-2,6-dione is ranging from about 1 to about 100. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je donor vodika mravlja kiselina; ili gdje se molarni omjer između mravlje kiseline 1 3-(2-metil-5-nitro-4-oksokinazolin-3(4H)-il)piperidin-2,6-diona može kretati u rasponu od otprilike 1 do otprilike 100, ili se može kretati u rasponu od otprilike 15 do otprilike 25.
A dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: 
PATENTNI ZAHTJEVI 1. -Dihidrospiro[cikloalkilamin|pirimidonski derivati, prikazani formulom (1) ili njegova sol, ili njen solvat ili hidrat:
A compound of Formula II: or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof, wherein: 
Spoj s Formulom II: [image] ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol, naznačen time da: A je CONHOH;
The Trichoderma or Myceliophthora cell of claim 1, wherein said polynucleotide encoding the heterologous catalytic subunit of oligosaccharyltransferase comprises a nucleic acid selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 88 and SEQ ID NO: 90 or a polynucleotide encoding a functional variant polypeptide having at least 50%, at least 60%, at least 70% identity, at least 80% identity, at least 90% identity, or at least 95% identity with SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 89 or SEQ ID NO:91, said functional variant polypeptide having oligosaccharyltransferase activity. 
Stanica gljivice Trichoderma ili Myceliophtora sukladno zahtjevu 1, pri čemu navedeni polinukleotid koji kodira heterolognu katalitičku podjedinicu oligosaharila transferaze uključuje nukleinsku kiselinu odabranu iz skupine koja obuhvaća SEQ ID NO; 2, SEQ ID NO: 9, SEQ ID NO: 88 i SEQ ID NO: 90 ili polinukleotid koji kodira funkcionalni varijantni polipeptid s najmanje 50%, 60%, 70%, 80%, 90% ili 95% podudarnosti s SEQ ID NO: 1, SEQ ID NO: 8, SEQ ID NO: 89 ili SEQ ID NO:91, pri čemu funkcionalni varijantni polipeptid ima aktivnost oligosaharila transferaze.
The method of claim 6 wherein the non-crystallising sugar or non-crystallising sugar alcohol (a)(ii) is a non-crystallising form of sorbitol, a non-crystallising form of xylitol or a mixture of a non-crystallising form of sorbitol and a non-crystallising form of xylitol. 
Tableta-pastila prema patentnom zahtjevu 15, naznačena time što je ne-kristalizirajući šećer ili ne-kristalizirajući šećerni alkohol ne-kristalizirajući oblik sorbitola, ne-kristalizirajući ksilitol ili smjesa ne-kristalizirajućeg sorbitola i ne-kristalizirajućeg ksilitola. Tableta-pastila prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se najmanje 50% komponente (11) sastoji od ne-kristalizirajućeg oblika sorbitola.
The resulting solution was flushed with nitrogen. A catalyst (10%Pd/C with 50% water, 99.1 g) was added and the flask was flushed with nitrogen three times and then with hydrogen three times. 
Dobivena otopina je bila isprana s dušikom Katalizator (10% Pd/C s 50% vode, 99.1 g) je bio dodan 1 tikvica je bila preplavljena s dušikom tri puta i tada tri puta s vodikom.
Excess acid added during synthesis or added after synthesis has a similarly detrimental effect. Use of a compound comprising a cobalt-bearing alkyd polymer as a polymerization agent in coatings, said polymer comprising cobalt carboxylate sequences, and having a cobalt content of 0.5 to 6% by weight, and a mean molecular weight of more than 3000. 
Spoj za upotrebu kao sredstvo za polimerizaciju u premazima, koji sadrži alkidni polimer s kobaltom sa sadržajem kobalta od 0,5 do 6 % po masi, s prosječnom molekulskom masom većom od 3000 1 s karboksilatnim sekvencama kobalta, čija je značajka to što navedeni polimer ima kiselost manju od 40 mg KOH/g, a poželjno manju od 20 mg KOH/g.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 3, wherein said cancer is a solid tumor. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje je navedeni rak solidni tumor.
A demountable pole dancing stage as claimed in claim 1, wherein at least one of the support members is provided with a bar, which is arranged to retain weights. 
Sklopiva pozornica za ples na šipki 1z bilo kojeg prethodnog zahtjeva, pri čemu bar jedan od nosivih elemenata ima okomitu šipku smještenu ispod gornje površine nosivog elementa i predviđenu za zadržavanje težine.
When the unit gets to value 400, it will roll over to 10. Scrolling will be at an accelerated rate of 4 to 10 characters per second during the hold down interval. 
Kada jedinica dođe do vrijednosti 400, prijeći će na vrijednost 10, Premotavanje će biti ubrzano na 4 do 10 znakova u sekundi tijekom intervala pritiskanja gumba.
Water was added and the product was extracted into ethyl acetate. 
Doda se voda, a produkt ekstrahira u etil-acetat.
was added slowly over 30 minutes to a stirred solution of tetrabenazine RR / SS racemate (15g, 47 mmol) in ethanol (75 ml) and tetrahydrofuran (75 ml) at 0 °C, After addition was complete the mixture was stirred at 0 °C for 30 minutes and then allowed to warm to room temperature. 
se polagano tijekom 30 minuta dodaje u miješanu otopinu tetrabenazin RR/SS racemata (15 g, 47 mmol) u etanolu (75 ml) i tetrahidrofuranu (75 ml) na 0 "C, Nakon završenog dodavanja smjesa se miješa na 0 "C tijekom 30 minuta i zatim se ostavi ugrijati na sobnu temperaturu.
said core comprises an active ingredient comprising at least one of a pharmaceutical, veterinary, or nutraceutical active ingredient; 
navedena jezgra obuhvaća djelotvorni sastojak koji sadrži najmanje jedan farmaceutski, veterinarski ili nutraceutski djelotvorni sastojak;
Roofing or wall covering having a plurality of rows of roofing or wall covering elements (1) which adjoin one another and are laid in an overlapping manner, at least some of the roofing or wall covering elements being fastened or being capable of being fastened mechanically in a reversibly releasable manner to the roof or wall substructure (4) by way of the respective complementary fastening element (6, 9) which is attached or can be attached to a roof or wall substructure and/or the underlying roofing or wall covering element, said at least some of the roofing or wall covering elements being a roofing or wall covering element for laying in an overlapping manner with other roofing or wall covering elements, said roofing or wall covering element comprises o a first surface for providing outer surface of said roof or wall covering; 
Krovni ili zidni pokrov koji ima mnoštvo redova krovnih elemenata ili elemenata zidne obloge (1) koji graniče jedni s drugima i postavljaju se na preklapajući način, barem neki krovni elementi ili elementi zidne obloge su učvršćeni ili su sposobni da ih se pričvrsti na mehanički na povratno oslobodiv način na podstrukturu krova ili zida (4) pomoću odgovarajućeg komplementarnog elementa za učvršćivanje (6, 9) koji je priključen ili može biti priključen na podstrukturu krova ili zida i/ili temeljni krovni element ili element zidne obloge, navedeni barem neki krovni elementi ili elementi zidne obloge su krovni elementi ili elementi zidne obloge za postavljanje na preklapajući način s drugim krovnim elementima ili elementima zidnih obloga, te navedeni krovni elementi ili elementi zidnih obloga sadrže o prvu površinu za osiguravanje vanjske površine navedene krovne ili zidne obloge;